Test Price
2,800 AED✅ Home Collection Available
KRT17 Gene Pachyonychia Congenita Type 2 Genetic Test in UAE | 2,800 AED | DHA Certified
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Next-Generation Sequencing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM – 11 PM).
- Clinical Guidance: Post-Test Telephonic Genetic Counseling by a Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The KRT17 gene NGS test identifies pathogenic variants associated with Pachyonychia Congenita Type 2, a rare autosomal dominant skin disorder characterized by nail thickening, palmoplantar keratoderma, and oral leukokeratosis. This molecular analysis enables definitive diagnosis, facilitates early intervention, and guides genetic counseling for affected families. The test employs next-generation sequencing of the full coding region and splice sites of the KRT17 gene, achieving 99.9% sensitivity for point mutations and small insertions/deletions.
| Feature | DNA Labs UAE | Closest Alternative |
|---|---|---|
| Methodology | Next-Generation Sequencing (NGS) – comprehensive full coding region analysis | Single‑gene Sanger sequencing (limited variant coverage) |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Diagnostic Sensitivity | 99.9% for point mutations, small indels within KRT17 | ~95% (limited to selected exons) |
Physician Insight & Safety Protocols
"As a Consultant Medical Geneticist, I understand the profound impact of a confirmed genetic diagnosis on families grappling with Pachyonychia Congenita. This NGS‑based test offers definitive molecular evidence to guide tailored management and reproductive decisions. However, results must always be interpreted alongside clinical presentation and family history. A negative result does not exclude the condition if clinical suspicion remains high – further investigation may be warranted."
– Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA: 9294403)
Safety Advisory & Pre-Test Instructions
Safety Exclusion Criteria & Emergency Red Flags
- Not indicated for minors without valid guardian consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Avoid self-withdrawal of prescribed medications (including systemic retinoids or immunosuppressants) before sample collection without prior consultation with your treating physician.
- Emergency Red Flags: If you develop severe blistering accompanied by high fever, breathing difficulties, or signs of systemic infection (e.g., sepsis), seek immediate emergency medical care – do not wait for test results.
Exclusion Criteria
- Individuals with a prior bone marrow transplant (due to donor-derived DNA interference).
- Active hematological malignancy or recent blood transfusion within the past 7 days (may affect peripheral blood cell‑based analysis).
Patient FAQ & Clinical Guidance
1. What is the purpose of the KRT17 gene test?
This test detects mutations in the KRT17 gene that cause Pachyonychia Congenita type 2, enabling a precise molecular diagnosis. It uses next-generation sequencing to analyze the entire coding region of the KRT17 gene, identifying pathogenic variants responsible for this rare autosomal dominant condition. The result confirms clinical suspicion, guides treatment planning, and informs family risk assessment.
2. How is the sample collected and what is the turnaround time?
Sample collection is performed via VIP Mobile Phlebotomy at your home (available daily 8 AM–11 PM). A trained phlebotomist obtains a peripheral blood sample (2–5 mL in EDTA tube) using sterile technique. The specimen is transported to our ISO‑accredited genetics laboratory in a temperature‑controlled cold chain. Results are delivered electronically within 21–28 calendar days (3–4 weeks).
3. What do the results mean for my health and my family?
A positive result confirms a pathogenic variant in KRT17, providing a definitive diagnosis and enabling targeted management including dermatologic care, pain management, and genetic counseling for at‑risk relatives. A negative result does not completely exclude the disease if clinical features are strong – it may indicate a mutation in a different gene or a non‑coding variant. All reports include a complimentary telephonic genetic counseling session with a licensed medical geneticist.
4. Is the test covered by insurance in the UAE?
Many UAE insurance policies cover genetic testing for rare diseases. We offer direct billing verification – simply send a copy of your insurance card via WhatsApp to +971 54 548 8731 and our team will confirm coverage and any copay amounts within 24 hours.
5. How should I prepare for the sample collection?
No special preparation is required. You may eat and drink normally. Please inform the phlebotomist if you are taking any blood‑thinning medications. Avoid applying heavy lotions or creams to the venipuncture site on the morning of collection. Please have your Emirates ID or passport available for identity verification.
UAE Regulatory & Data Privacy Adherence
This service fully complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is processed and stored exclusively within the United Arab Emirates under strict confidentiality protocols. Laboratory accreditation: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). Genetic counseling adheres to DHA‑MOHAP standards. Patient consent and medical liability are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | KRT17 Gene Pachyonychia Congenita Type 2 Genetic Test – NGS Sequencing |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks (21–28 Calendar Days) |
| Sample Type / Matrix | Peripheral Whole Blood – EDTA (2‑5 mL) – VIP Mobile Phlebotomy & Cold‑Chain Home Collection |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full Coding Region & Splice Sites of KRT17 |
| ICD-10-CM Code | Q82.8 (Other specified congenital malformations of skin) |
| LOINC Code | 21636-6 (Molecular pathology, genetic analysis) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians